RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)

Recruiting

RAD 1802: A Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)

Who can join

Ages 18 to 99 · All sexes

Full eligibility criteria

Inclusion Criteria:

* Pathologically proven invasive mammary carcinoma, Invasive ductal carcinoma (IDC) or ductal carcinoma in situ (DCIS) of the breast. Medullary, papillary, mucinous (colloid) and tubular histologies are allowed.
* Age\>50.
* Maximum pathologic tumor size \<2.0cm if invasive carcinoma or \< 2.5cm if pure DCIS.
* Estrogen receptor (ER) positive (\>10%).
* Must be eligible for breast conservation therapy and receive a lumpectomy with pathologic margins of at least 2mm.
* Must be clinically node negative by physical examination. Sentinel node dissection is not required, but if undertaken, the patient must be pathologically node negative.
* Zubrod Performance Status 0-2.

Exclusion Criteria:

* Multifocal or multicentric cancer.
* Reception of neoadjuvant chemotherapy.
* Pure invasive lobular histology.
* Inability to clearly delineate lumpectomy cavity on post lumpectomy planning scan.
* Measured maximum PTV of \>124cc.
* Lumpectomy cavity within 5mm of body contour.

About the study

This study offers 5 fractions of radiation treatment through partial breast irradiation in patients with early stage breast cancer after having a lumpectomy.

What is being tested

5 Fraction Stereotactic Body Radiation Therapy (radiation)

Sponsor: University of Alabama at Birmingham · Participants: 40 · Started: Aug 20, 2019

Contact the study team

D. Hunter Boggs, MD · Phone: (205) 934-5670
D. Hunter Boggs, MD · Phone: (205) 975-5581

Official record on ClinicalTrials.gov — NCT03643861

Locations in the U.S.

Alabama

University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham

Conditions

Breast Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.